Patrick O'Brien - Jan 5, 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Signature
/s/ Patrick O'Brien
Stock symbol
ARWR
Transactions as of
Jan 5, 2022
Transactions value $
-$2,005,875
Form type
4
Date filed
1/7/2022, 07:16 PM
Previous filing
Jan 4, 2022
Next filing
Dec 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$752K -12.4K -3.26% $60.49 369K Jan 5, 2022 Direct F1, F2
transaction ARWR Common Stock Sale -$640K -10.4K -2.81% $61.88 359K Jan 5, 2022 Direct F1, F3
transaction ARWR Common Stock Sale -$312K -5K -1.39% $62.49 354K Jan 5, 2022 Direct F1, F4
transaction ARWR Common Stock Sale -$281K -4.4K -1.24% $63.75 349K Jan 5, 2022 Direct F1, F5
transaction ARWR Common Stock Sale -$20.3K -316 -0.09% $64.35 349K Jan 5, 2022 Direct F1, F6
transaction ARWR Common Stock Gift $0 -800 -0.23% $0.00 348K Dec 4, 2020 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $62.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.09 to $63.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.19 to $64.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F6 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.